UCB To Buy Ra for $2.1bn And Plays Down Antitrust Fears

Getting hold of zilucoplan, a 'pipeline in a product'

The deal, welcomed by analysts, means that the Belgian drug maker has two late-stage products for the rare disease myasthenia gravis to challenge Alexion's Soliris.

Chess_Pawns
Deal unites two leaders in myasthenia gravis • Source: Shutterstock

UCB Group looks to have done a very smart bit of business by agreeing to buy Ra Pharmaceuticals Inc. for $2.1bn and get access to the potential blockbuster zilucoplan for the neuromuscular condition myasthenia gravis (MG) and other rare diseases.

The Belgian drugmaker is paying $48 a share in cash for Cambridge, MA-based Ra, which represents a 111% premium to...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Deals

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.